Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)

Central Pharmaceuticals Cash Flow Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-21.98	-43.96	-43.96	-68.25	-8.47
Depreciation & Amortization	21.61	13.45	26.75	29.76	32.89
Other Amortization	0.01	0.01	0.01	0.01	-
Asset Writedown & Restructuring Costs	-	0.18	-	-	-
Other Operating Activities	-7.2	19.67	0.01	17.47	21.32
Change in Accounts Receivable	4.35	7.14	-1.3	-0.05	-23.03
Change in Inventory	-6.46	3.8	17.12	20.58	-7.41
Change in Accounts Payable	10.43	4.21	3.79	0.85	-1.39
Change in Income Taxes	0.2	4.25	0.18	0.16	0.89
Change in Other Net Operating Assets	-0.57	0.26	1.16	1.07	-5.95
Operating Cash Flow	-0.52	2.97	-0.33	-1.12	1.8
Capital Expenditures	-	-	-	-	-6.57
Investing Cash Flow	-	-	-	-	-6.57
Short-Term Debt Issued	-	-	-	9.12	-
Long-Term Debt Issued	-	-	-	7.92	25.21
Total Debt Issued	-	-	-	17.04	25.21
Net Debt Issued (Repaid)	-	-	-	17.04	25.21
Other Financing Activities	-0.01	-0.01	-0.01	-17.47	-21.45
Financing Cash Flow	-0.01	-0.01	-0.01	-0.43	3.76
Net Cash Flow	-0.52	2.96	-0.34	-1.55	-1.02
Free Cash Flow	-0.52	2.97	-0.33	-1.12	-4.78
Free Cash Flow Margin	-1.57%	10.02%	-1.11%	-4.31%	-3.22%
Free Cash Flow Per Share	-0.00	0.03	-0.00	-0.01	-0.04
Cash Interest Paid	0.01	0.01	-	17.36	21.36
Cash Income Tax Paid	-0	0	0.35	0.11	5.95
Levered Free Cash Flow	19.07	4	17.79	8.19	-19.67
Unlevered Free Cash Flow	19.07	4	17.79	19.04	-6.32
Change in Working Capital	7.04	13.62	16.86	19.89	-43.95

Updated Dec 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.